Endra Life Sciences INC Form 4 insider transactions

ASP Isotopes Inc. announced that its subsidiary, Tetra4 Proprietary Limited (a Renergen Limited subsidiary), has entered into a new five-year take-or-pay contract for the sale of liquified natural gas (LNG) from the Virginia Gas Project.

ASP Isotopes Inc. announced its participation in Citi's 2026 Natural Resources Conference, including investor meetings, and provided an update on its proposed merger with ENDRA Life Sciences Inc.

ASP Isotopes Inc. updates shareholders on strong progress in PET Labs and Renergen, with helium production set to commence and significant EBITDA targets projected.

ASPI Isotopes Inc. and ENDRA Life Sciences Inc. have announced plans for a merger, aiming to create a combined entity focused on helium and LNG production.

ASP Isotopes (Noble Africa) details proposed merger with ENDRA Life Sciences, highlighting the critical global helium shortage and the unique Virginia Gas Project.

ASP Isotopes and ENDRA Life Sciences are hosting an investor webinar to discuss the proposed merger of Noble Africa, an ASP Isotopes subsidiary focused on helium and LNG, with ENDRA.

ENDRA Life Sciences and ASP Isotopes are merging, creating a public helium company, Noble Africa, focused on Renergen's Virginia Gas Project.

ENDRA Life Sciences has entered into a definitive merger agreement with Noble Africa LLC, a subsidiary of ASP Isotopes, to create a combined company focused on helium and LNG resources.

ASP Isotopes' subsidiary, Noble Africa, will merge with ENDRA Life Sciences, creating a Nasdaq-listed helium platform and securing $50 million in financing.

ENDRA Life Sciences announced a merger with Noble Africa, a subsidiary of ASP Isotopes, alongside a $50 million private placement.

ENDRA Life Sciences CEO Alexander Tokman acquired 26,921 restricted stock units, increasing his beneficial ownership to 101,926 shares.

ENDRA Life Sciences Inc.'s Chief Financial Officer, Richard Jacroux, acquired 13,461 restricted stock units, increasing his beneficial ownership.

ENDRA Life Sciences Director Anthony DiGiandomenico was granted 60,324 restricted stock units, vesting in full by January 21, 2027.

ENDRA Life Sciences Director Michael Harsh was granted 60,324 restricted stock units, vesting in January 2026.

ENDRA Life Sciences Inc.'s Chief Financial Officer, Richard Jacroux, was granted 20,000 restricted stock units, vesting fully on January 21, 2027.

ENDRA Life Sciences Director Lou Basenese was granted 60,324 restricted stock units, aligning his interests with shareholders.

ENDRA Life Sciences CEO Alexander Y. Tokman was granted 75,000 restricted stock units, vesting in full on January 21, 2027.

Anthony DiGiandomenico, a Director at ENDRA Life Sciences Inc., plans to acquire 70,822 shares of common stock and 141,644 warrants in a private placement on October 10, 2025.

ENDRA Life Sciences Inc. Director Lou Basenese was granted 5,384 restricted stock units (RSUs) on June 11, 2025, which will vest in full on June 11, 2026.

Michael Harsh, a Director at ENDRA Life Sciences Inc., was granted 5,384 restricted stock units (RSUs) on June 11, 2025, which will vest in full on June 11, 2026.

ENDRA Life Sciences Inc. Director Anthony DiGiandomenico was granted 5,384 restricted stock units, which are scheduled to vest in full on June 11, 2026.

UBS Group AG files an amended Form 4 to correct a previous filing, stating they never beneficially owned more than 10% of ENDRA Life Sciences Inc. shares due to warrant exercises affecting the total outstanding share count.

UBS Group AG, through its subsidiaries, reports the acquisition and disposition of ENDRA Life Sciences Inc. common stock.